VERVE-102: One Infusion for Durable Cholesterol Reduction — Analysis of Heart-2 Data from NEJM

Some people are born with the PCSK9 gene effectively switched off. Their LDL cholesterol remains low throughout life, and their cardiovascular risk is exceptionally low. Scientist Sekar Kathiresan studied this natural genetic observation roughly 20 years ago and turned it into a central therapeutic idea: build a medicine that can pharmacologically mimic this protective genetic state. In May 2026, the first clinical data for VERVE-102 were published in NEJM.

LDL-C reduction is one of the most evidence-backed strategies in atherosclerotic cardiovascular disease prevention. In practice, however, many high-risk patients discontinue or fail to maintain long-term use of statins, ezetimibe, or injectable PCSK9 inhibitors such as evolocumab and alirocumab. Daily tablets or recurring injections are not realistic for everyone. VERVE-102 is designed to address this adherence gap through a one-time gene-editing intervention targeting hepatic PCSK9 production.

VERVE-102 was developed by Verve Therapeutics, now an Eli Lilly subsidiary. It consists of adenine base editor mRNA, a guide RNA targeting the PCSK9 gene, and a GalNAc lipid nanoparticle (LNP) delivery system for liver cells. The mechanism is based on a single-base DNA edit that functionally inactivates PCSK9 in the liver. With less PCSK9, LDL receptors remain longer on the surface of hepatocytes and can clear more LDL-C from circulation.

VERVE-102 uses adenine base editing, meaning it chemically changes a specific DNA base without relying on a classic double-strand DNA break. In theory, this may reduce some risks associated with full DNA cuts. Even so, the technology remains early in human cardiometabolic application and requires long-term monitoring for off-target editing, immune reactions, and durability.

Heart-2 was an early Phase 1 study in 35 adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease. Mean baseline LDL-C was approximately 129 mg/dL, and 91% of participants were already receiving statin therapy. Trial dose cohorts showed dose-dependent PCSK9 reduction from 51% at 0.3 mg/kg to 88% at 1.0 mg/kg, while LDL-C was reduced by up to 62% at the highest studied dose. Absolute LDL-C reduction at 1.0 mg/kg was reported at approximately 78 mg/dL.

One of the most important elements in the Heart-2 data is durability. Effects were sustained for up to 18 months in some participants, with median follow-up of roughly 9 months at the February 2026 cutoff. Fifteen patients had at least 12 months of follow-up. This supports the hypothesis of long duration, but it does not yet prove a lifelong effect or cardiovascular outcome benefit.

In early Heart-2 data, no treatment-related serious adverse events and no dose-limiting toxicities were reported. Adverse events were mainly mild infusion-related reactions and transient ALT increases without clinical significance. One serious adverse event, aspiration pneumonia, was judged unrelated to treatment. No participant discontinued the study. This is encouraging, but it does not close the safety case for a permanent gene-editing technology.

Heart-2 is a Phase 1 study with a small patient population. It was not designed to measure major cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality. In addition, in vivo gene-editing technologies require extended follow-up, often up to 15 years, to evaluate off-target effects, long-term safety, and durability. The data are important, but still early.

VERVE-102 has received FDA Fast Track Designation, and a Phase 2 trial is expected toward the end of 2026. In parallel, Verve's platform is expanding with VERVE-201, an ANGPTL3-targeting program being evaluated in the Pulse-1 Phase 1b trial. The clinical and commercial value of the platform will depend on whether LDL-C reductions translate into real cardiovascular outcomes and whether long-term safety remains clean.

The Heart-2 data provide early evidence that in vivo PCSK9 base editing can deliver meaningful and durable LDL-C reduction after a single therapeutic intervention. This is not an approved treatment. Phase 2 data, cardiovascular outcome data, and long-term safety follow-up remain essential before any broad clinical application.